(1) Río C del, Millán E, García V, Appendino G, DeMesa J and Muñoz E. The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders. Biochem. Pharmacol. (2018) 157: 122–33.
(2) McPartland JM. The endocannabinoid system: an osteopathic perspective. J. Am. Osteopath. Assoc. (2008) 108: 586–600.
(3) Fride E and Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur. J. Pharmacol. (1993) 231: 313–14.
(4) Devane WA, Hanuš L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 258: 1946–49.
(5) Kerbrat A, Ferré JC, Fillatre P, Ronzière T, Vannier S, Carsin-Nicol B, Lavoué S, Vérin M, Gauvrit JY, Le Tulzo Y and Edan G. Acute neurologic disorder from an inhibitor of fatty acid amide hydrolase. N. Engl. J. Med. (2016) 375: 1717–25.
(6) Deplano A, Morgillo CM, Demurtas M, Björklund E, Cipriano M, Svensson M, Hashemian S, Smaldone G, Pedone E, Luque FJ, Cabiddu MG, Novellino E, Fowler CJ, Catalanotti B and Onnis V. Novel propanamides as fatty acid amide hydrolase inhibitors. Eur. J. Med. Chem. (2017) 136: 523–42.
(7) Burman MA, Szolusha K, Bind R, Kerney K, Boger DL and Bilsky EJ. FAAH inhibitor OL-135 disrupts contextual, but not auditory, fear conditioning in rats. Behav. Brain Res. (2016) 308: 1–5.
(8) Otrubova K, Ezzili C and Boger DL. The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH). Bioorg. Med. Chem. Lett. (2011) 21: 4674–85.
(9) Boger DL, Sato H, Lerner AE, Hedrick MP, Fecik RA, Miyauchi H, Wilkie GD, Austin BJ, Patricelli MP and Cravatt BF. Exceptionally potent inhibitors of fatty acid amide hydrolase: The enzyme responsible for degradation of endogenous oleamide and anandamide. Proc. Natl. Acad. Sci. U. S. A. (2000): 97: 5044–49.
(10) Taylor RD, Maccoss M and Lawson ADG. Rings in drugs. J. Med. Chem. (2014) 57: 5845–59.
(11) Tokumaru K and Johnston JN. A convergent synthesis of 1,3,4-oxadiazoles from acyl hydrazides under semiaqueous conditions. Chem. Sci. (2017) 8: 3187–91.
(12) Zavareh ER, Hedayati M, Rad LH, Shahhosseini S, Faizi M and Tabatabai SA. Design, synthesis and biological evaluation of 4-benzamidobenzoic acid hydrazide derivatives as novel soluble epoxide hydrolase inhibitors. Iran. J. Pharma. Res. (2014) 13: 51.
(13) Demare P and Regla I. Synthesis of two local anesthetics from toluene: an organic multistep synthesis in a project-oriented laboratory course. J. Chem. Educ. (2012) 89: 147–49.
(14) Dunetz JR, Magano J and Weisenburger GA. Large-scale applications of amide coupling reagents for the synthesis of pharmaceuticals. Org. Process Res. Dev. (2016) 20: 140–77
(15) Soliman R and Darwish SAS. Antidiabetic activity of some 1-substituted 3,5-dimethylpyrazoles. J. Med. Chem. (1983) 26: 1659–63.